中华妇产科杂志
中華婦產科雜誌
중화부산과잡지
CHINESE JOUNAL OF OBSTETRICS AND GYNECOLOGY
2008年
4期
272-275
,共4页
段萍%程静%林明%蔡莲莲%胡哲%金诗湘%胡明品
段萍%程靜%林明%蔡蓮蓮%鬍哲%金詩湘%鬍明品
단평%정정%림명%채련련%호철%금시상%호명품
子宫内膜异位症%栓塞,治疗性%藻酸盐%微球体%治疗结果
子宮內膜異位癥%栓塞,治療性%藻痠鹽%微毬體%治療結果
자궁내막이위증%전새,치료성%조산염%미구체%치료결과
Endometriosis%Embolization,therapeutic%Alginates%Microspheres%Treatmentoutcome
目的 观察直径500~700μm的海藻酸钠微球(KMG)超选择栓塞子宫动脉,治疗弥漫型子宫腺肌病(AD)的中远期临床疗效.方法 选择经药物治疗后无效、自愿接受子宫动脉栓塞术(UAE)治疗的弥漫型AD患者40例,以直径500~700μm的KMG超选择插管栓塞子宫动脉,治疗后3、6、12、24、36、48、60个月随访,分别观察月经量、痛经评分、子宫体积、女性内分泌激素和血清CA125水平变化.结果 (1)随访率:40例患者完成了治疗后3、6、12、24个月的随访,随访率为100%;治疗后36、48和60个月的随访例数分别为32、27和23例,随访率分别为80%、68%和58%.(2)临床指标:治疗后3个月,有效率90%(36/40),无效率10%(4/40);治疗后36个月,有效率88%(28/32),无效率12%(4/32);治疗后60个月,有效率83%(19/23),无效率17%(4/23),无一例复发.治疗后3个月的月经量、痛经评分、子宫体积分别为(182±8)ml、(46±21)分、(212±35)cm3,分别与治疗前比较,差异均有统计学意义(P<0.05);治疗后6个月的月经量、痛经评分分别为(140±6)ml、(25±16)分,分别与治疗前比较,差异也有统计学意义(P<0.01);子宫体积于治疗后12个月时缩至最小,为(135±38)cm3.(3)血清学指标:治疗后12个月,血清CA125水平下降至最低值,为(56±18)U/L,与治疗前比较,差异有统计学意义(P<0.01),但始终未下降至正常值;女性内分泌激素水平无明显变化(P>0.05).结论 直径500~700 μm的KMG超选择栓塞子宫动脉治疗弥漫型AD的中远期疗效满意,对卵巢功能无明显影响.
目的 觀察直徑500~700μm的海藻痠鈉微毬(KMG)超選擇栓塞子宮動脈,治療瀰漫型子宮腺肌病(AD)的中遠期臨床療效.方法 選擇經藥物治療後無效、自願接受子宮動脈栓塞術(UAE)治療的瀰漫型AD患者40例,以直徑500~700μm的KMG超選擇插管栓塞子宮動脈,治療後3、6、12、24、36、48、60箇月隨訪,分彆觀察月經量、痛經評分、子宮體積、女性內分泌激素和血清CA125水平變化.結果 (1)隨訪率:40例患者完成瞭治療後3、6、12、24箇月的隨訪,隨訪率為100%;治療後36、48和60箇月的隨訪例數分彆為32、27和23例,隨訪率分彆為80%、68%和58%.(2)臨床指標:治療後3箇月,有效率90%(36/40),無效率10%(4/40);治療後36箇月,有效率88%(28/32),無效率12%(4/32);治療後60箇月,有效率83%(19/23),無效率17%(4/23),無一例複髮.治療後3箇月的月經量、痛經評分、子宮體積分彆為(182±8)ml、(46±21)分、(212±35)cm3,分彆與治療前比較,差異均有統計學意義(P<0.05);治療後6箇月的月經量、痛經評分分彆為(140±6)ml、(25±16)分,分彆與治療前比較,差異也有統計學意義(P<0.01);子宮體積于治療後12箇月時縮至最小,為(135±38)cm3.(3)血清學指標:治療後12箇月,血清CA125水平下降至最低值,為(56±18)U/L,與治療前比較,差異有統計學意義(P<0.01),但始終未下降至正常值;女性內分泌激素水平無明顯變化(P>0.05).結論 直徑500~700 μm的KMG超選擇栓塞子宮動脈治療瀰漫型AD的中遠期療效滿意,對卵巢功能無明顯影響.
목적 관찰직경500~700μm적해조산납미구(KMG)초선택전새자궁동맥,치료미만형자궁선기병(AD)적중원기림상료효.방법 선택경약물치료후무효、자원접수자궁동맥전새술(UAE)치료적미만형AD환자40례,이직경500~700μm적KMG초선택삽관전새자궁동맥,치료후3、6、12、24、36、48、60개월수방,분별관찰월경량、통경평분、자궁체적、녀성내분비격소화혈청CA125수평변화.결과 (1)수방솔:40례환자완성료치료후3、6、12、24개월적수방,수방솔위100%;치료후36、48화60개월적수방례수분별위32、27화23례,수방솔분별위80%、68%화58%.(2)림상지표:치료후3개월,유효솔90%(36/40),무효솔10%(4/40);치료후36개월,유효솔88%(28/32),무효솔12%(4/32);치료후60개월,유효솔83%(19/23),무효솔17%(4/23),무일례복발.치료후3개월적월경량、통경평분、자궁체적분별위(182±8)ml、(46±21)분、(212±35)cm3,분별여치료전비교,차이균유통계학의의(P<0.05);치료후6개월적월경량、통경평분분별위(140±6)ml、(25±16)분,분별여치료전비교,차이야유통계학의의(P<0.01);자궁체적우치료후12개월시축지최소,위(135±38)cm3.(3)혈청학지표:치료후12개월,혈청CA125수평하강지최저치,위(56±18)U/L,여치료전비교,차이유통계학의의(P<0.01),단시종미하강지정상치;녀성내분비격소수평무명현변화(P>0.05).결론 직경500~700 μm적KMG초선택전새자궁동맥치료미만형AD적중원기료효만의,대란소공능무명현영향.
Objective To study intermediate and long term efficacy of uterine arterial embolization (UAE)with sodium alginate microspheres(KMG)at diameters 500-700μm in treatment of diffuse adenomyosis.Methods Totally 40 patients with standard difluse adenomyosis were enrolled and treated with UAE.KMG at diameters 500-700 μm for vascular embolization were used to embolize the arteries.The degree of dysmenorrhea,amount of menorrhea and uterine volume,as well as the level of serum CA125,follicle stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E2)were investigated before andafter UAE.Results The follow up rates were 100%(40/40),100%(40/40),80%(32/40),68%(27/40),58%(23/40)after uterine arterial UAE 12,24,36,48 and 60 months respectively.The early,intermediate and long-term effective rates were 90%(36/40),88%(28/32),83%(19/23).The degree of dysmenorrhea,the amount of menorrhea and the uterine volume,as well as serum CA125 all decreased significantly 3 mouths after UAE at varying degrees(P<0.05).Compared with other follow-up time,thedegree of dysmenorrhea and the amount of menorrhea declined to their lowest point at 6 month after UAE (P<0.01).Paralleled with the decrease of volume of uterine,serum CA125 also decreased significantly and reached the lowest level 12 months later compared with other follow-up times(P<0.01).Even at the 12th month after UAE serum CA125was not normal and FSH,LH and E2 did not change all the times after UAE(P>0.05).No recurrence was found during the 60 months after UAE.Condusion KMG used in UAE at diameters 500-700 μm has good intermediate and long term effectiveness in treatment of diffuse adenomyosis with no side effects.